Premium
Propofol in subanesthetic doses terminates status epilepticus in a rodent model
Author(s) -
Holtkamp Martin,
Tong Xin,
Walker Matthew C.
Publication year - 2001
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/1531-8249(20010201)49:2<260::aid-ana49>3.0.co;2-y
Subject(s) - propofol , status epilepticus , rodent model , anesthesia , rodent , medicine , neuroscience , psychology , pharmacology , epilepsy , biology , ecology
Status epilepticus is commonly refractory to first‐line therapy, and thus better treatments are needed. We have investigated an experimental model of drug‐resistant self‐sustaining status epilepticus (SSSE) induced by 2 hours of perforant path stimulation. Propofol in subanesthetic doses administered shortly after the end of stimulation and also after a further 3 hours of SSSE terminated the SSSE without recurrence. This finding calls for a trial of propofol in refractory status epilepticus and also raises the possibility of using it as first‐line therapy. Ann Neurol 2001;49:260–263